Business Context and Reporting Period
Company: Hercules Technology Growth Capital, Inc. (HTGC)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2014
Business Overview: HTGC is an internally managed, non-diversified closed-end investment company regulated as a Business Development Company (BDC) and taxed as a Regulated Investment Company (RIC). The company focuses on providing senior secured loans to venture capital-backed companies in technology-related markets, including biotechnology, life sciences, and energy technology.
Key Financial Metrics
| Metric | Q1 2014 | Q1 2013 |
|---|---|---|
| Total Assets | $1,159.4 million | $1,221.7 million (Dec 31, 2013) |
| Total Investments (at value) | $890.7 million | $910.3 million (Dec 31, 2013) |
| Total Liabilities | $506.1 million | $571.7 million (Dec 31, 2013) |
| Net Assets | $653.3 million | $650.0 million (Dec 31, 2013) |
| Net Asset Value (NAV) per Share | $10.58 | $10.51 (Dec 31, 2013) |
| Net Investment Income | $18.3 million | $15.0 million |
| Net Realized Gain on Investments | $4.9 million | $2.0 million |
| Net Change in Unrealized Appreciation | $(1.0) million | $(0.3) million |
| Net Increase in Net Assets from Operations | $22.2 million | $16.7 million |
| Cash and Cash Equivalents | $224.5 million | $268.4 million (Dec 31, 2013) |
| Dividends Declared per Share | $0.31 | $0.27 |
Material Changes vs. Prior Period
- Investment Portfolio: Total portfolio value decreased by approximately $19.6 million from December 31, 2013, to March 31, 2014. This decline was driven by principal repayments and early payoffs totaling approximately $132.6 million, partially offset by new fundings of approximately $110.4 million in debt and $1.5 million in equity.
- Income Growth: Net investment income increased by 21.8% year-over-year, primarily due to accelerations related to early payoffs and loan modifications. Fee income more than doubled to $4.9 million from $2.0 million.
- Realized Gains: Net realized gains increased significantly to $4.9 million from $2.0 million in the prior year, driven by sales of investments in five portfolio companies (including Cell Therapeutics and Neuralstem) and liquidation of others.
- Debt Reduction: The company repaid $34.8 million of SBA debentures and $25.8 million of Asset-Backed Notes during the quarter, reducing total liabilities.
- Unrealized Depreciation: The portfolio recorded a net unrealized depreciation of $1.0 million, primarily due to $10.3 million in warrant depreciation and $2.7 million in debt depreciation, partially offset by $12.0 million in equity appreciation.
Guidance, Outlook, and Risks
- Liquidity: As of March 31, 2014, the company held $329.5 million in available liquidity, including $224.5 million in cash and cash equivalents. Available borrowing capacity included $75.0 million under the Wells Facility and $30.0 million under the Union Bank Facility.
- Dividend Policy: The Board declared a quarterly dividend of $0.31 per share, payable May 19, 2014. The company intends to distribute approximately $3.8 million of spillover earnings from 2013 in 2014.
- Commitments: Unfunded contractual commitments totaled $189.4 million, with approximately $95.6 million dependent on portfolio companies reaching specific milestones. Non-binding term sheets totaled $238.0 million.
- Risks:
- Valuation Risk: Approximately 76.8% of total assets are Level 3 investments valued in good faith by the Board, which may differ significantly from market values if a liquid market existed.
- Concentration Risk: The top four industries (Drug Discovery, Energy Technology, Internet Services, Medical Devices) comprised 64.9% of the portfolio.
- Non-Accrual Status: Three debt investments were on non-accrual status with a fair value of $7.7 million.
- Regulatory Compliance: As a BDC and RIC, the company must maintain specific asset coverage ratios and distribution requirements to avoid corporate-level taxation.
Key Facts for Investor Verification
- NAV vs. Market Price: Verify the discount/premium of the stock price ($14.07 market value per share) relative to the reported NAV ($10.58 per share).
- Warrant Portfolio Performance: Review the significant decline in the warrant portfolio value (down 33.7% from year-end 2013) and the impact of warrant exercises on realized gains.
- Debt Yield and Cost: Confirm the effective yield on debt investments (17.9% for Q1 2014) versus the weighted average cost of debt (6.9% for Q1 2014).
- Asset Coverage Ratio: Verify the asset coverage ratio of 312.8% (excluding SBA debentures) and 231.4% (including SBA debentures) to ensure compliance with BDC regulations.
- Unfunded Commitments: Assess the company's ability to fund the $189.4 million in contractual commitments given current cash flows and borrowing capacity.